Q1 26 EPS
$2.55
BEAT +17.33%
Est. $2.17
Q1 26 Revenue
$64.01B
BEAT +8.00%
Est. $59.27B
vs S&P Since Q1 26
+15.4%
BEATING MARKET
CAH +25.0% vs S&P +9.6%
Market Reaction
Did CAH Beat Earnings? Q1 2026 Results
Cardinal Health kicked off fiscal 2026 with a decisive beat on both the top and bottom lines, as the healthcare distribution giant reported first-quarter revenue of $64.01 billion, up 22.4% year-over-year and ahead of the $59.27 billion consensus by … Read more Cardinal Health kicked off fiscal 2026 with a decisive beat on both the top and bottom lines, as the healthcare distribution giant reported first-quarter revenue of $64.01 billion, up 22.4% year-over-year and ahead of the $59.27 billion consensus by 8.00%, while non-GAAP diluted EPS of $2.55 cleared the $2.17 analyst estimate by 17.33%. The primary engine behind the outperformance was the Pharmaceutical and Specialty Solutions segment, where revenue climbed 23% to $59.20 billion and segment profit rose 26% to $667.00 million, fueled by robust brand and specialty pharmaceutical sales, positive generics program performance, and contributions from MSO platform acquisitions. The Global Medical Products and Distribution segment also turned a meaningful corner, with segment profit jumping to $46.00 million from just $8.00 million a year earlier. Management responded to the strong results by raising full-year non-GAAP EPS guidance to $9.65 to $9.85, representing 17% to 20% growth, while investors are weighing whether the stock's sharp post-earnings appreciation has pulled valuation ahead of fundamentals.
Key Takeaways
- • Brand and specialty pharmaceutical sales growth from existing and new customers
- • Positive generics program performance
- • Contributions from MSO platform acquisitions
- • Advanced Diabetes Supply acquisition contributing to at-Home Solutions growth
- • Volume growth from existing customers in GMPD
- • Lower share count and lower effective tax rate boosting non-GAAP EPS
- • Growth across all five operating segments
CAH YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
CAH Revenue by Segment
With YoY comparisons, source: SEC Filings
“We are pleased with our strong broad-based operational and financial performance to begin fiscal 2026. This outstanding first quarter reflects our focused execution across each of our operating segments and provides a solid foundation as we carry forward. As a result, we are raising our fiscal 2026 outlook.”
— Jason Hollar, Q1 2026 Earnings Press Release
CAH Earnings Trends
CAH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CAH EPS Trend
Earnings per share: estimate vs actual
CAH Revenue Trend
Quarterly revenue: estimate vs actual
CAH Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q3 26 BEAT | $2.79 | $3.17 | +13.70% | $60.94B | -2.19% |
| Q2 26 BEAT | $2.37 | $2.63 | +11.17% | $65.63B | +0.60% |
| Q1 26 BEAT | $2.17 | $2.55 | +17.33% | $64.01B | +8.00% |
| Q4 25 MISS FY | $2.18 | $2.08 | -4.70% | $60.16B | +1.26% |
| FY Full Year | $9.43 | $8.24 | -12.65% | $222.58B | -0.33% |
| Q3 25 BEAT | $2.15 | $2.35 | +9.36% | $54.88B | -0.78% |